ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
April 04, 2024 07:57 ET
|
ZyVersa Therapeutics
Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14, 2024 07:57 ET
|
ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
December 06, 2023 07:20 ET
|
ZyVersa Therapeutics
AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
Endothelial Dysfunction Market to Reach $2.58Bn, Globally, by 2028 at 4.4% CAGR with Hypertension Segment Driving Growth During 2022-2028 | Report by The Insight Partners
August 11, 2023 06:41 ET
|
The Insight Partners
Pune, India, Aug. 11, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on “Endothelial Dysfunction Market Size Report & Share, Forecast to 2028 – COVID-19 Impact and...
Curcumin Market Growth Analysis Report - $135.5 Million, Globally, by 2028 at 9.1% CAGR – Comprehensive Study by The Insight Partners
March 20, 2023 10:54 ET
|
The Insight Partners
New York, March 20, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Curcumin Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by...
Kizoo Portfolio Company Underdog Closes $10M Financing Round
September 23, 2021 07:00 ET
|
KIZOO Technology Capital GmbH
MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital....
Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators
September 08, 2021 11:00 ET
|
Underdog Pharmaceuticals Inc.
MOUNTAIN VIEW, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related...
Inflation Devices Market Size to Reach Valuation of $770 million by 2026 | AMR
February 15, 2021 10:00 ET
|
Allied Market Research
Portland, OR, Feb. 15, 2021 (GLOBE NEWSWIRE) -- According to the report, the global inflation devices market was valued at $517 million in 2018, and is expected to reach $770 million by 2026,...
Clinical Highlights: 15th Annual CMHC Live Online
October 29, 2020 13:09 ET
|
Cardiometabolic Health Congress
Boca Raton, FL, Oct. 29, 2020 (GLOBE NEWSWIRE) -- The 15th Annual CMHC Live Online concluded on Saturday, October 24th. For the first time in its history, the event was delivered entirely online to...
Novel therapeutic approach to cardiovascular disease from SENS Research Foundation flagship research program graduates from laboratory to the biotech world
November 14, 2019 07:00 ET
|
SENS Research Foundation
Kizoo Technology Capital leads seed round financing at Underdog Pharmaceuticals SRF announces leadership appointments MOUNTAIN VIEW, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Underdog...